Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Neurocrine Biosciences (NBIX) Invested Capital (2016 - 2026)

Neurocrine Biosciences filings provide 16 years of Invested Capital readings, the most recent being $3.3 billion for Q4 2025.

  • On a quarterly basis, Invested Capital rose 25.62% to $3.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $3.3 billion, a 25.62% increase, with the full-year FY2025 number at $3.3 billion, up 25.62% from a year prior.
  • Invested Capital hit $3.3 billion in Q4 2025 for Neurocrine Biosciences, up from $3.0 billion in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $3.3 billion in Q4 2025 to a low of $1.2 billion in Q1 2021.
  • Median Invested Capital over the past 5 years was $2.1 billion (2023), compared with a mean of $2.1 billion.
  • Biggest five-year swings in Invested Capital: decreased 1.0% in 2021 and later soared 48.94% in 2024.
  • Neurocrine Biosciences' Invested Capital stood at $1.4 billion in 2021, then soared by 36.62% to $1.9 billion in 2022, then rose by 27.96% to $2.4 billion in 2023, then rose by 7.81% to $2.6 billion in 2024, then rose by 25.62% to $3.3 billion in 2025.
  • The last three reported values for Invested Capital were $3.3 billion (Q4 2025), $3.0 billion (Q3 2025), and $2.7 billion (Q2 2025) per Business Quant data.